| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 142 | 2024 | 3000 | 18.470 |
Why?
|
| Genetic Predisposition to Disease | 62 | 2024 | 2335 | 4.790 |
Why?
|
| Genome-Wide Association Study | 33 | 2024 | 1670 | 3.480 |
Why?
|
| Female | 239 | 2024 | 46014 | 3.080 |
Why?
|
| Healthcare Disparities | 8 | 2024 | 410 | 2.890 |
Why?
|
| Polymorphism, Single Nucleotide | 49 | 2024 | 2399 | 2.680 |
Why?
|
| Biomarkers, Tumor | 22 | 2024 | 1543 | 2.480 |
Why?
|
| Estrogen Receptor alpha | 9 | 2024 | 147 | 2.460 |
Why?
|
| Middle Aged | 153 | 2024 | 25865 | 2.430 |
Why?
|
| Humans | 274 | 2024 | 89073 | 2.290 |
Why?
|
| Genes, BRCA1 | 13 | 2019 | 192 | 2.290 |
Why?
|
| Germ-Line Mutation | 15 | 2024 | 344 | 2.240 |
Why?
|
| Diethylstilbestrol | 9 | 2021 | 119 | 2.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 9 | 2021 | 158 | 2.150 |
Why?
|
| Adult | 135 | 2024 | 26508 | 2.080 |
Why?
|
| Prognosis | 37 | 2024 | 3773 | 2.060 |
Why?
|
| Mastectomy | 6 | 2023 | 245 | 2.040 |
Why?
|
| Receptors, Progesterone | 10 | 2024 | 174 | 2.010 |
Why?
|
| Aged | 97 | 2024 | 19078 | 1.980 |
Why?
|
| Neoadjuvant Therapy | 7 | 2024 | 373 | 1.970 |
Why?
|
| Case-Control Studies | 40 | 2024 | 1855 | 1.940 |
Why?
|
| Triple Negative Breast Neoplasms | 10 | 2024 | 152 | 1.870 |
Why?
|
| Transcriptome | 5 | 2024 | 628 | 1.790 |
Why?
|
| Genes, BRCA2 | 8 | 2019 | 161 | 1.770 |
Why?
|
| Receptors, Estrogen | 17 | 2024 | 393 | 1.770 |
Why?
|
| Nigeria | 31 | 2024 | 156 | 1.610 |
Why?
|
| Risk Factors | 52 | 2024 | 5466 | 1.600 |
Why?
|
| Substance Abuse, Intravenous | 9 | 2009 | 59 | 1.540 |
Why?
|
| Neoplasms, Second Primary | 7 | 2014 | 260 | 1.510 |
Why?
|
| Quantitative Trait Loci | 4 | 2024 | 607 | 1.500 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1363 | 1.490 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2024 | 158 | 1.350 |
Why?
|
| Neoplasm Staging | 21 | 2024 | 2001 | 1.340 |
Why?
|
| Receptor, ErbB-2 | 13 | 2024 | 245 | 1.340 |
Why?
|
| Needle-Exchange Programs | 7 | 2009 | 18 | 1.330 |
Why?
|
| Breast Neoplasms, Male | 5 | 2017 | 31 | 1.330 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2024 | 115 | 1.310 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2021 | 296 | 1.280 |
Why?
|
| BRCA1 Protein | 14 | 2019 | 204 | 1.230 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2018 | 62 | 1.200 |
Why?
|
| Aged, 80 and over | 43 | 2024 | 6777 | 1.190 |
Why?
|
| Vaginal Neoplasms | 2 | 2018 | 84 | 1.180 |
Why?
|
| Genetic Loci | 9 | 2024 | 253 | 1.180 |
Why?
|
| United States | 28 | 2024 | 6957 | 1.160 |
Why?
|
| Carcinoma, Lobular | 4 | 2015 | 81 | 1.130 |
Why?
|
| Mutation | 23 | 2023 | 4132 | 1.120 |
Why?
|
| Complementary Therapies | 3 | 2024 | 56 | 1.120 |
Why?
|
| Cohort Studies | 26 | 2023 | 2863 | 1.090 |
Why?
|
| Urology | 7 | 2020 | 117 | 1.080 |
Why?
|
| Breast Diseases | 2 | 2024 | 100 | 1.030 |
Why?
|
| Databases, Factual | 11 | 2021 | 850 | 1.030 |
Why?
|
| Body Mass Index | 11 | 2021 | 771 | 1.030 |
Why?
|
| BRCA2 Protein | 10 | 2019 | 161 | 1.010 |
Why?
|
| Precision Medicine | 4 | 2024 | 410 | 1.010 |
Why?
|
| Survival Analysis | 18 | 2024 | 1533 | 1.000 |
Why?
|
| Mastectomy, Segmental | 5 | 2024 | 101 | 0.990 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 599 | 0.960 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 295 | 0.960 |
Why?
|
| Genetic Testing | 8 | 2023 | 537 | 0.920 |
Why?
|
| Biomedical Research | 8 | 2024 | 398 | 0.920 |
Why?
|
| Risk-Taking | 7 | 2009 | 155 | 0.910 |
Why?
|
| Logistic Models | 16 | 2017 | 1212 | 0.900 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 848 | 0.870 |
Why?
|
| Needle Sharing | 6 | 2007 | 15 | 0.870 |
Why?
|
| Yoga | 1 | 2023 | 5 | 0.870 |
Why?
|
| Meditation | 1 | 2023 | 5 | 0.870 |
Why?
|
| Neoplasms | 10 | 2024 | 3035 | 0.870 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 95 | 0.860 |
Why?
|
| Retrospective Studies | 26 | 2024 | 9003 | 0.860 |
Why?
|
| Body Weight | 3 | 2021 | 452 | 0.860 |
Why?
|
| Ovarian Neoplasms | 9 | 2019 | 763 | 0.840 |
Why?
|
| Metabolome | 1 | 2023 | 49 | 0.840 |
Why?
|
| Carcinoma | 4 | 2015 | 443 | 0.830 |
Why?
|
| Guideline Adherence | 4 | 2019 | 229 | 0.810 |
Why?
|
| Machine Learning | 1 | 2024 | 257 | 0.810 |
Why?
|
| Glucuronosyltransferase | 7 | 2014 | 186 | 0.800 |
Why?
|
| Palliative Care | 1 | 2024 | 263 | 0.790 |
Why?
|
| Menarche | 1 | 2021 | 29 | 0.790 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2412 | 0.780 |
Why?
|
| Young Adult | 21 | 2024 | 6289 | 0.740 |
Why?
|
| Standard of Care | 1 | 2021 | 65 | 0.740 |
Why?
|
| Telemedicine | 1 | 2023 | 185 | 0.730 |
Why?
|
| Withholding Treatment | 1 | 2021 | 117 | 0.730 |
Why?
|
| Follow-Up Studies | 19 | 2024 | 3657 | 0.730 |
Why?
|
| Breast | 8 | 2023 | 292 | 0.720 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2024 | 1265 | 0.710 |
Why?
|
| Neoplasm Metastasis | 10 | 2024 | 1108 | 0.710 |
Why?
|
| Male | 98 | 2024 | 42254 | 0.700 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 65 | 0.700 |
Why?
|
| Radiation Injuries | 1 | 2021 | 160 | 0.700 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 114 | 0.700 |
Why?
|
| Age Factors | 16 | 2023 | 1867 | 0.690 |
Why?
|
| Women's Health | 3 | 2021 | 102 | 0.690 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2347 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2024 | 412 | 0.660 |
Why?
|
| Pandemics | 2 | 2023 | 771 | 0.650 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 667 | 0.640 |
Why?
|
| Program Evaluation | 5 | 2011 | 306 | 0.640 |
Why?
|
| MicroRNAs | 4 | 2016 | 551 | 0.630 |
Why?
|
| Incidence | 14 | 2021 | 1592 | 0.620 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1706 | 0.610 |
Why?
|
| Haptoglobins | 1 | 2017 | 9 | 0.600 |
Why?
|
| Body Height | 4 | 2021 | 100 | 0.600 |
Why?
|
| Prostatic Neoplasms | 12 | 2020 | 1768 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 257 | 0.590 |
Why?
|
| Parity | 4 | 2015 | 96 | 0.590 |
Why?
|
| Early Detection of Cancer | 7 | 2018 | 415 | 0.590 |
Why?
|
| Adolescent | 27 | 2020 | 9237 | 0.580 |
Why?
|
| Bayes Theorem | 2 | 2016 | 369 | 0.580 |
Why?
|
| Genomics | 3 | 2024 | 761 | 0.570 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 329 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.560 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 485 | 0.560 |
Why?
|
| Circulating MicroRNA | 1 | 2016 | 13 | 0.560 |
Why?
|
| Ribonuclease III | 1 | 2016 | 16 | 0.550 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 156 | 0.550 |
Why?
|
| Brachytherapy | 2 | 2014 | 121 | 0.540 |
Why?
|
| Adenocarcinoma | 9 | 2018 | 1194 | 0.540 |
Why?
|
| Mendelian Randomization Analysis | 4 | 2019 | 44 | 0.540 |
Why?
|
| Genome, Human | 2 | 2020 | 767 | 0.540 |
Why?
|
| Neoplasm Grading | 5 | 2021 | 372 | 0.530 |
Why?
|
| Biological Products | 1 | 2018 | 153 | 0.520 |
Why?
|
| Pregnancy | 14 | 2021 | 3010 | 0.520 |
Why?
|
| Guidelines as Topic | 4 | 2020 | 160 | 0.520 |
Why?
|
| Lymph Node Excision | 3 | 2017 | 220 | 0.520 |
Why?
|
| Genotype | 17 | 2023 | 1848 | 0.520 |
Why?
|
| Odds Ratio | 8 | 2013 | 684 | 0.500 |
Why?
|
| Risk Assessment | 16 | 2024 | 2291 | 0.500 |
Why?
|
| Research Design | 7 | 2020 | 597 | 0.500 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 726 | 0.500 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 103 | 0.490 |
Why?
|
| Quality of Life | 5 | 2021 | 1662 | 0.480 |
Why?
|
| Mass Screening | 6 | 2018 | 636 | 0.470 |
Why?
|
| Survival Rate | 11 | 2023 | 1889 | 0.470 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 1241 | 0.470 |
Why?
|
| Chicago | 12 | 2021 | 1423 | 0.460 |
Why?
|
| Quality of Health Care | 1 | 2017 | 385 | 0.460 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 45 | 0.450 |
Why?
|
| Demography | 3 | 2023 | 181 | 0.450 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 27 | 0.450 |
Why?
|
| Alleles | 10 | 2024 | 1135 | 0.440 |
Why?
|
| Colonic Neoplasms | 3 | 2018 | 573 | 0.430 |
Why?
|
| Breast Feeding | 3 | 2012 | 102 | 0.430 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 168 | 0.430 |
Why?
|
| Population Surveillance | 3 | 2019 | 216 | 0.430 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 64 | 0.420 |
Why?
|
| Prospective Studies | 15 | 2024 | 4273 | 0.420 |
Why?
|
| Neoplasm Proteins | 4 | 2012 | 540 | 0.420 |
Why?
|
| Uganda | 5 | 2024 | 36 | 0.420 |
Why?
|
| Gene Expression Profiling | 9 | 2024 | 1429 | 0.420 |
Why?
|
| Lymphatic Metastasis | 4 | 2018 | 502 | 0.420 |
Why?
|
| Prostate-Specific Antigen | 5 | 2020 | 359 | 0.410 |
Why?
|
| Sexual Behavior | 2 | 2020 | 309 | 0.410 |
Why?
|
| Longitudinal Studies | 7 | 2023 | 1067 | 0.410 |
Why?
|
| Developed Countries | 1 | 2012 | 25 | 0.400 |
Why?
|
| Motor Activity | 1 | 2014 | 327 | 0.400 |
Why?
|
| HIV Infections | 6 | 2009 | 835 | 0.400 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 781 | 0.400 |
Why?
|
| Urban Population | 5 | 2019 | 224 | 0.390 |
Why?
|
| Genetic Association Studies | 8 | 2019 | 294 | 0.390 |
Why?
|
| Developing Countries | 1 | 2012 | 76 | 0.390 |
Why?
|
| Telomerase | 1 | 2011 | 62 | 0.390 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 754 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2023 | 859 | 0.380 |
Why?
|
| Health Status | 3 | 2014 | 370 | 0.380 |
Why?
|
| Lymph Nodes | 1 | 2015 | 548 | 0.380 |
Why?
|
| Colitis, Ulcerative | 7 | 2018 | 736 | 0.380 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 5 | 2010 | 54 | 0.370 |
Why?
|
| Health Surveys | 5 | 2021 | 240 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1176 | 0.370 |
Why?
|
| Diabetes Complications | 1 | 2012 | 170 | 0.370 |
Why?
|
| Cameroon | 4 | 2024 | 16 | 0.360 |
Why?
|
| Air Pollution, Indoor | 3 | 2017 | 64 | 0.360 |
Why?
|
| Registries | 5 | 2021 | 778 | 0.360 |
Why?
|
| Risk | 9 | 2021 | 657 | 0.360 |
Why?
|
| Time Factors | 10 | 2021 | 5320 | 0.360 |
Why?
|
| Health Status Disparities | 2 | 2023 | 187 | 0.350 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 988 | 0.350 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 25 | 0.340 |
Why?
|
| Africa | 4 | 2021 | 101 | 0.340 |
Why?
|
| Estrogens, Non-Steroidal | 2 | 2020 | 30 | 0.340 |
Why?
|
| Mammography | 4 | 2018 | 471 | 0.330 |
Why?
|
| Colorectal Neoplasms | 6 | 2015 | 981 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 313 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2552 | 0.330 |
Why?
|
| Prevalence | 8 | 2021 | 1240 | 0.330 |
Why?
|
| Endocrine Disruptors | 2 | 2019 | 27 | 0.330 |
Why?
|
| Biostatistics | 2 | 2019 | 20 | 0.320 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 109 | 0.320 |
Why?
|
| Introns | 4 | 2024 | 299 | 0.320 |
Why?
|
| SEER Program | 4 | 2014 | 197 | 0.320 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2007 | 357 | 0.310 |
Why?
|
| Maternal Exposure | 2 | 2019 | 58 | 0.310 |
Why?
|
| Gene Frequency | 7 | 2016 | 685 | 0.310 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 127 | 0.310 |
Why?
|
| Combined Modality Therapy | 7 | 2023 | 1710 | 0.300 |
Why?
|
| Treatment Outcome | 20 | 2024 | 8203 | 0.300 |
Why?
|
| Reinforcement, Verbal | 1 | 2007 | 5 | 0.300 |
Why?
|
| Mental Recall | 2 | 2015 | 157 | 0.290 |
Why?
|
| Radiotherapy | 1 | 2009 | 331 | 0.290 |
Why?
|
| Genetic Variation | 5 | 2019 | 1371 | 0.290 |
Why?
|
| Chromosome Aberrations | 5 | 2012 | 390 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2019 | 125 | 0.290 |
Why?
|
| Medical Records | 1 | 2007 | 120 | 0.280 |
Why?
|
| Disclosure | 1 | 2007 | 110 | 0.270 |
Why?
|
| Interleukin-11 | 3 | 2016 | 20 | 0.270 |
Why?
|
| Crohn Disease | 2 | 2018 | 758 | 0.270 |
Why?
|
| Cooking | 3 | 2017 | 56 | 0.270 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 157 | 0.270 |
Why?
|
| ROC Curve | 3 | 2024 | 781 | 0.270 |
Why?
|
| Computer Graphics | 3 | 2020 | 100 | 0.260 |
Why?
|
| Age Distribution | 3 | 2013 | 200 | 0.260 |
Why?
|
| Life Expectancy | 3 | 2015 | 89 | 0.260 |
Why?
|
| Statistics as Topic | 3 | 2020 | 234 | 0.260 |
Why?
|
| Immunologic Factors | 1 | 2007 | 171 | 0.260 |
Why?
|
| Rural Population | 5 | 2019 | 143 | 0.260 |
Why?
|
| Editorial Policies | 3 | 2020 | 34 | 0.250 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 171 | 0.250 |
Why?
|
| Postmenopause | 3 | 2013 | 102 | 0.250 |
Why?
|
| Azacitidine | 2 | 2024 | 146 | 0.250 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1215 | 0.250 |
Why?
|
| Smoke | 2 | 2016 | 27 | 0.250 |
Why?
|
| Data Interpretation, Statistical | 3 | 2020 | 299 | 0.250 |
Why?
|
| Heterozygote | 4 | 2019 | 373 | 0.240 |
Why?
|
| Immunohistochemistry | 7 | 2023 | 1796 | 0.240 |
Why?
|
| Integrative Medicine | 1 | 2024 | 10 | 0.240 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2007 | 138 | 0.240 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 345 | 0.240 |
Why?
|
| Primary Myelofibrosis | 1 | 2024 | 67 | 0.230 |
Why?
|
| Child | 14 | 2018 | 7149 | 0.230 |
Why?
|
| DNA Mutational Analysis | 8 | 2021 | 529 | 0.230 |
Why?
|
| Leukemia, Myeloid | 4 | 2012 | 249 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2008 | 788 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2024 | 244 | 0.230 |
Why?
|
| Reproductive History | 1 | 2003 | 10 | 0.230 |
Why?
|
| Biopsy | 7 | 2021 | 1182 | 0.230 |
Why?
|
| Multifactorial Inheritance | 3 | 2024 | 169 | 0.220 |
Why?
|
| Health Personnel | 2 | 2024 | 212 | 0.220 |
Why?
|
| Microfilament Proteins | 3 | 2016 | 212 | 0.220 |
Why?
|
| Linear Models | 4 | 2015 | 421 | 0.220 |
Why?
|
| Signal Transduction | 6 | 2018 | 3374 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 307 | 0.220 |
Why?
|
| Premature Birth | 2 | 2018 | 117 | 0.220 |
Why?
|
| Asthma | 3 | 2017 | 976 | 0.220 |
Why?
|
| Genetic Services | 1 | 2023 | 7 | 0.220 |
Why?
|
| Haplotypes | 6 | 2011 | 637 | 0.220 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 63 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2003 | 46 | 0.220 |
Why?
|
| Estrogens | 1 | 2024 | 201 | 0.220 |
Why?
|
| Jews | 2 | 2016 | 42 | 0.220 |
Why?
|
| Linkage Disequilibrium | 4 | 2013 | 477 | 0.210 |
Why?
|
| Diphosphonates | 3 | 2007 | 36 | 0.210 |
Why?
|
| Body Weights and Measures | 2 | 2021 | 27 | 0.210 |
Why?
|
| RNA Splicing | 1 | 2024 | 152 | 0.210 |
Why?
|
| Cell Line, Tumor | 12 | 2016 | 2553 | 0.210 |
Why?
|
| Metabolomics | 1 | 2023 | 75 | 0.210 |
Why?
|
| Bone Density Conservation Agents | 3 | 2007 | 46 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 126 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 5 | 2016 | 956 | 0.210 |
Why?
|
| Environmental Exposure | 2 | 2017 | 322 | 0.210 |
Why?
|
| Hormones | 1 | 2023 | 139 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2024 | 291 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 280 | 0.200 |
Why?
|
| Imidazoles | 3 | 2007 | 148 | 0.200 |
Why?
|
| Premenopause | 2 | 2013 | 57 | 0.200 |
Why?
|
| Database Management Systems | 1 | 2002 | 41 | 0.200 |
Why?
|
| Patient Satisfaction | 3 | 2023 | 461 | 0.200 |
Why?
|
| Clonal Evolution | 1 | 2021 | 15 | 0.200 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 625 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 80 | 0.200 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.190 |
Why?
|
| Birth Weight | 3 | 2019 | 145 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1401 | 0.190 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2008 | 67 | 0.190 |
Why?
|
| Comorbidity | 3 | 2021 | 948 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 1239 | 0.190 |
Why?
|
| Nitric Oxide | 3 | 2010 | 279 | 0.190 |
Why?
|
| Up-Regulation | 3 | 2016 | 727 | 0.190 |
Why?
|
| Obesity | 4 | 2013 | 966 | 0.190 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2018 | 77 | 0.190 |
Why?
|
| Neoplasms, Basal Cell | 2 | 2011 | 9 | 0.190 |
Why?
|
| Datasets as Topic | 2 | 2019 | 75 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 4 | 2011 | 866 | 0.190 |
Why?
|
| Social Isolation | 1 | 2021 | 67 | 0.190 |
Why?
|
| beta Catenin | 2 | 2015 | 266 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2021 | 102 | 0.180 |
Why?
|
| Gallbladder Diseases | 1 | 2020 | 23 | 0.180 |
Why?
|
| Sequence Deletion | 2 | 2019 | 205 | 0.180 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 69 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2016 | 159 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 576 | 0.180 |
Why?
|
| Trans-Activators | 3 | 2021 | 443 | 0.180 |
Why?
|
| Medicine, African Traditional | 1 | 2020 | 3 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2021 | 91 | 0.180 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 332 | 0.180 |
Why?
|
| United Kingdom | 1 | 2020 | 164 | 0.180 |
Why?
|
| Soybean Proteins | 1 | 2019 | 5 | 0.180 |
Why?
|
| Soy Foods | 1 | 2019 | 3 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1715 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 424 | 0.170 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2019 | 4 | 0.170 |
Why?
|
| Capecitabine | 1 | 2020 | 98 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 192 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2024 | 382 | 0.170 |
Why?
|
| Propensity Score | 1 | 2020 | 147 | 0.170 |
Why?
|
| Gender Identity | 1 | 2020 | 53 | 0.170 |
Why?
|
| Polymorphism, Genetic | 3 | 2008 | 824 | 0.170 |
Why?
|
| Radiotherapy Dosage | 4 | 2014 | 470 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2023 | 341 | 0.170 |
Why?
|
| Models, Statistical | 3 | 2021 | 575 | 0.170 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 582 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 90 | 0.170 |
Why?
|
| Menstruation Disturbances | 1 | 2018 | 24 | 0.160 |
Why?
|
| DNA Repair | 3 | 2011 | 362 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 32 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1837 | 0.160 |
Why?
|
| DNA Methylation | 2 | 2016 | 657 | 0.160 |
Why?
|
| Homologous Recombination | 1 | 2018 | 52 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2612 | 0.150 |
Why?
|
| Developmental Disabilities | 3 | 2010 | 202 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 69 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2006 | 1096 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 203 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1043 | 0.150 |
Why?
|
| Medicare | 1 | 2021 | 423 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 9 | 0.150 |
Why?
|
| Child Development | 2 | 2009 | 167 | 0.150 |
Why?
|
| ras Proteins | 2 | 2011 | 130 | 0.150 |
Why?
|
| Age of Onset | 5 | 2018 | 312 | 0.150 |
Why?
|
| Chromosome Mapping | 3 | 2019 | 1076 | 0.150 |
Why?
|
| Bone Density | 3 | 2007 | 209 | 0.150 |
Why?
|
| Carcinogens | 1 | 2017 | 111 | 0.150 |
Why?
|
| Genomic Instability | 2 | 2021 | 80 | 0.140 |
Why?
|
| Base Sequence | 5 | 2012 | 2327 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 64 | 0.140 |
Why?
|
| Harm Reduction | 2 | 2007 | 17 | 0.140 |
Why?
|
| Confidence Intervals | 3 | 2013 | 225 | 0.140 |
Why?
|
| Depression | 2 | 2019 | 503 | 0.140 |
Why?
|
| Lumbar Vertebrae | 2 | 2008 | 151 | 0.140 |
Why?
|
| China | 3 | 2021 | 233 | 0.140 |
Why?
|
| Travel | 1 | 2017 | 71 | 0.140 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 111 | 0.140 |
Why?
|
| Postpartum Period | 2 | 2018 | 144 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2018 | 132 | 0.140 |
Why?
|
| Africa South of the Sahara | 3 | 2023 | 21 | 0.140 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2007 | 108 | 0.140 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hepacivirus | 2 | 2016 | 129 | 0.140 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 556 | 0.140 |
Why?
|
| Pedigree | 2 | 2016 | 969 | 0.130 |
Why?
|
| Chemoprevention | 2 | 2014 | 92 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 185 | 0.130 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.130 |
Why?
|
| Minority Groups | 2 | 2009 | 144 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 144 | 0.130 |
Why?
|
| Double-Blind Method | 7 | 2010 | 1715 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 112 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 531 | 0.130 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 159 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2008 | 251 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2016 | 287 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 308 | 0.130 |
Why?
|
| Lymphoma, T-Cell | 2 | 2007 | 55 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 345 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2016 | 119 | 0.130 |
Why?
|
| Directly Observed Therapy | 1 | 2015 | 5 | 0.130 |
Why?
|
| Vitamin D | 1 | 2017 | 268 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2018 | 323 | 0.120 |
Why?
|
| Drug Users | 1 | 2015 | 20 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2016 | 183 | 0.120 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 54 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2014 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 695 | 0.120 |
Why?
|
| Deoxycytidine | 3 | 2006 | 238 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2007 | 102 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 665 | 0.120 |
Why?
|
| Cytoskeleton | 2 | 2013 | 195 | 0.120 |
Why?
|
| Microsatellite Repeats | 2 | 2012 | 147 | 0.120 |
Why?
|
| Physicians | 1 | 2022 | 689 | 0.120 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2005 | 43 | 0.120 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 306 | 0.120 |
Why?
|
| Vasospasm, Intracranial | 2 | 2004 | 35 | 0.120 |
Why?
|
| Interferon Type I | 1 | 2015 | 178 | 0.120 |
Why?
|
| Family Health | 2 | 2011 | 162 | 0.120 |
Why?
|
| Infant, Premature | 5 | 2010 | 295 | 0.110 |
Why?
|
| CpG Islands | 2 | 2016 | 157 | 0.110 |
Why?
|
| Pathology | 1 | 2013 | 32 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 3 | 2006 | 1063 | 0.110 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2013 | 12 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 44 | 0.110 |
Why?
|
| Tuberculosis | 1 | 2015 | 121 | 0.110 |
Why?
|
| Mice | 13 | 2023 | 11742 | 0.110 |
Why?
|
| Overweight | 2 | 2011 | 119 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2007 | 833 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2013 | 79 | 0.110 |
Why?
|
| Quinazolines | 2 | 2005 | 221 | 0.110 |
Why?
|
| Indians, North American | 1 | 2013 | 47 | 0.110 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 31 | 0.110 |
Why?
|
| Neurosurgical Procedures | 2 | 2007 | 232 | 0.110 |
Why?
|
| Vimentin | 1 | 2012 | 46 | 0.110 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2013 | 63 | 0.110 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 805 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3443 | 0.110 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 10 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2657 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2013 | 269 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 25 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 429 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 424 | 0.100 |
Why?
|
| Epigenomics | 1 | 2013 | 103 | 0.100 |
Why?
|
| Mesalamine | 2 | 2003 | 88 | 0.100 |
Why?
|
| Lactation | 1 | 2012 | 54 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2007 | 894 | 0.100 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 20 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 13 | 0.100 |
Why?
|
| Remission Induction | 3 | 2012 | 740 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 217 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 176 | 0.100 |
Why?
|
| Allergens | 1 | 2013 | 183 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2016 | 198 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 122 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 273 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 171 | 0.100 |
Why?
|
| E-Box Elements | 1 | 2011 | 5 | 0.100 |
Why?
|
| Data Collection | 2 | 2023 | 375 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 681 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 705 | 0.090 |
Why?
|
| Survivors | 2 | 2015 | 233 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2003 | 242 | 0.090 |
Why?
|
| Pregnatrienes | 3 | 2007 | 14 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 170 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 146 | 0.090 |
Why?
|
| Child Health Services | 1 | 2011 | 48 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 177 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 377 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2015 | 230 | 0.090 |
Why?
|
| Gene Fusion | 1 | 2010 | 39 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2011 | 84 | 0.090 |
Why?
|
| Schools | 1 | 2011 | 75 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2010 | 77 | 0.090 |
Why?
|
| Electroconvulsive Therapy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 146 | 0.090 |
Why?
|
| RecQ Helicases | 1 | 2009 | 7 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2007 | 44 | 0.090 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 12 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 21 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 481 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 2007 | 243 | 0.090 |
Why?
|
| Headache | 1 | 2010 | 72 | 0.090 |
Why?
|
| Community Health Services | 1 | 2011 | 82 | 0.090 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.090 |
Why?
|
| MAP Kinase Kinase 6 | 2 | 2007 | 12 | 0.090 |
Why?
|
| Orchiectomy | 2 | 2007 | 72 | 0.090 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 87 | 0.090 |
Why?
|
| Reading | 1 | 2009 | 31 | 0.090 |
Why?
|
| Inflammation | 2 | 2013 | 971 | 0.090 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 507 | 0.090 |
Why?
|
| Neuroprotective Agents | 3 | 2007 | 100 | 0.090 |
Why?
|
| Exons | 2 | 2010 | 451 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 66 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 682 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2010 | 130 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 447 | 0.080 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 172 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 287 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2007 | 235 | 0.080 |
Why?
|
| Cumulus Cells | 1 | 2008 | 7 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 264 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 163 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 9 | 0.080 |
Why?
|
| Rad51 Recombinase | 1 | 2009 | 80 | 0.080 |
Why?
|
| Attitude to Health | 2 | 2011 | 222 | 0.080 |
Why?
|
| DNA Replication | 1 | 2009 | 170 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 38 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 616 | 0.080 |
Why?
|
| Core Binding Factors | 1 | 2008 | 12 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2009 | 1652 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2009 | 81 | 0.080 |
Why?
|
| Condoms | 1 | 2009 | 38 | 0.080 |
Why?
|
| Depsipeptides | 1 | 2008 | 30 | 0.080 |
Why?
|
| Animals | 14 | 2023 | 27324 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2009 | 45 | 0.080 |
Why?
|
| Spinal Diseases | 1 | 2008 | 44 | 0.080 |
Why?
|
| Coculture Techniques | 1 | 2008 | 173 | 0.080 |
Why?
|
| Exome | 2 | 2019 | 127 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2016 | 470 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 23 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Decision Making | 1 | 2014 | 665 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 92 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 142 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 116 | 0.080 |
Why?
|
| GATA3 Transcription Factor | 2 | 2021 | 48 | 0.080 |
Why?
|
| Fatty Liver | 1 | 2009 | 95 | 0.080 |
Why?
|
| Oocytes | 1 | 2008 | 221 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 193 | 0.080 |
Why?
|
| Sexual Partners | 1 | 2009 | 100 | 0.080 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 60 | 0.080 |
Why?
|
| Spinal Fusion | 1 | 2008 | 86 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 315 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2006 | 197 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2008 | 107 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2008 | 478 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2007 | 35 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2011 | 401 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 400 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 604 | 0.070 |
Why?
|
| Infant, Newborn | 6 | 2010 | 2476 | 0.070 |
Why?
|
| Spinal Osteophytosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 996 | 0.070 |
Why?
|
| Aneurysm, Ruptured | 1 | 2007 | 54 | 0.070 |
Why?
|
| Mouth Neoplasms | 1 | 2009 | 198 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 53 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 382 | 0.070 |
Why?
|
| Urologic Neoplasms | 1 | 2008 | 82 | 0.070 |
Why?
|
| Swine | 1 | 2008 | 581 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 571 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2009 | 97 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Bilirubin | 1 | 2007 | 129 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 336 | 0.070 |
Why?
|
| Back Pain | 1 | 2007 | 42 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 2 | 2007 | 338 | 0.070 |
Why?
|
| Spinal Stenosis | 1 | 2007 | 25 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 210 | 0.070 |
Why?
|
| Aminosalicylic Acids | 1 | 2006 | 41 | 0.070 |
Why?
|
| Respiratory Sounds | 2 | 2017 | 34 | 0.070 |
Why?
|
| Child, Preschool | 6 | 2011 | 3717 | 0.070 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2006 | 18 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 202 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2010 | 567 | 0.070 |
Why?
|
| Mortality | 1 | 2007 | 149 | 0.070 |
Why?
|
| Walking | 1 | 2007 | 89 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2007 | 87 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2006 | 396 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 280 | 0.070 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
| Life Style | 1 | 2007 | 172 | 0.070 |
Why?
|
| Pilot Projects | 4 | 2014 | 865 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 165 | 0.070 |
Why?
|
| Software | 3 | 2020 | 665 | 0.070 |
Why?
|
| Infliximab | 1 | 2007 | 159 | 0.070 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 154 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 106 | 0.070 |
Why?
|
| Obstetric Labor, Premature | 1 | 2006 | 58 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2018 | 263 | 0.070 |
Why?
|
| Barbados | 2 | 2018 | 7 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 122 | 0.070 |
Why?
|
| Intracranial Aneurysm | 1 | 2007 | 175 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 151 | 0.070 |
Why?
|
| S100 Proteins | 1 | 2005 | 51 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2016 | 114 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2010 | 245 | 0.060 |
Why?
|
| Animal Identification Systems | 1 | 2005 | 3 | 0.060 |
Why?
|
| Alloys | 1 | 2005 | 10 | 0.060 |
Why?
|
| Data Display | 2 | 2020 | 24 | 0.060 |
Why?
|
| Hepatitis C | 2 | 2005 | 170 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 557 | 0.060 |
Why?
|
| Ear, External | 1 | 2005 | 26 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2005 | 54 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 200 | 0.060 |
Why?
|
| Syringes | 1 | 2005 | 13 | 0.060 |
Why?
|
| Contrast Media | 1 | 2010 | 1090 | 0.060 |
Why?
|
| Complement C4b | 1 | 2005 | 32 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2006 | 170 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2007 | 216 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 125 | 0.060 |
Why?
|
| Sex Factors | 3 | 2016 | 1063 | 0.060 |
Why?
|
| Cladribine | 1 | 2004 | 35 | 0.060 |
Why?
|
| Capillaries | 1 | 2005 | 90 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2005 | 161 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2010 | 1214 | 0.060 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2004 | 34 | 0.060 |
Why?
|
| Operating Rooms | 1 | 2005 | 129 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2005 | 187 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 359 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2021 | 337 | 0.060 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 38 | 0.060 |
Why?
|
| Marital Status | 1 | 2023 | 42 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2752 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 352 | 0.050 |
Why?
|
| Biomarkers | 3 | 2018 | 1755 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2007 | 889 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 3027 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 463 | 0.050 |
Why?
|
| Diet | 2 | 2019 | 442 | 0.050 |
Why?
|
| RNA Interference | 2 | 2016 | 376 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2003 | 133 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 186 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 62 | 0.050 |
Why?
|
| Vinblastine | 1 | 2002 | 108 | 0.050 |
Why?
|
| Leukomalacia, Periventricular | 3 | 2009 | 18 | 0.050 |
Why?
|
| Colonoscopy | 2 | 2018 | 279 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 802 | 0.050 |
Why?
|
| Administration, Inhalation | 3 | 2010 | 190 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2006 | 395 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2013 | 96 | 0.050 |
Why?
|
| Extremities | 1 | 2003 | 169 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 130 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 32 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2021 | 11 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 921 | 0.050 |
Why?
|
| Neuropsychological Tests | 3 | 2009 | 505 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 590 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 63 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 181 | 0.050 |
Why?
|
| Recurrence | 3 | 2012 | 1140 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2003 | 262 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 29 | 0.050 |
Why?
|
| Suburban Population | 1 | 2001 | 6 | 0.050 |
Why?
|
| Sarcoma | 1 | 2003 | 220 | 0.050 |
Why?
|
| Mice, Transgenic | 4 | 2007 | 1574 | 0.050 |
Why?
|
| Cell Survival | 2 | 2015 | 982 | 0.050 |
Why?
|
| Disease Progression | 3 | 2012 | 1488 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2021 | 71 | 0.050 |
Why?
|
| Family | 2 | 2018 | 325 | 0.050 |
Why?
|
| Taxoids | 1 | 2021 | 130 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2022 | 157 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2004 | 423 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2012 | 268 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2004 | 342 | 0.050 |
Why?
|
| Protein Binding | 3 | 2009 | 1487 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 716 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 321 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 1940 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2011 | 779 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 579 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2019 | 16 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 53 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2006 | 575 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 887 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 96 | 0.040 |
Why?
|
| Health Behavior | 2 | 2011 | 184 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 435 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 76 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 65 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2005 | 1067 | 0.040 |
Why?
|
| Palpation | 1 | 2018 | 18 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 73 | 0.040 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2003 | 516 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 71 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 225 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2011 | 2011 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 68 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 45 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 849 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 459 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 295 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2018 | 83 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 635 | 0.040 |
Why?
|
| Observer Variation | 2 | 2013 | 610 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 163 | 0.040 |
Why?
|
| Physical Examination | 1 | 2018 | 148 | 0.040 |
Why?
|
| Mothers | 1 | 2018 | 142 | 0.040 |
Why?
|
| Acute Disease | 2 | 2012 | 841 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2880 | 0.040 |
Why?
|
| Reproduction | 1 | 2018 | 199 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 2281 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 227 | 0.040 |
Why?
|
| Liver | 2 | 2013 | 1205 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1310 | 0.040 |
Why?
|
| Biomass | 1 | 2017 | 36 | 0.040 |
Why?
|
| MAP Kinase Kinase 7 | 2 | 2007 | 21 | 0.040 |
Why?
|
| High Mobility Group Proteins | 1 | 2016 | 26 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2011 | 405 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 466 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1650 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 27 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 149 | 0.030 |
Why?
|
| Serum Response Factor | 1 | 2016 | 45 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 55 | 0.030 |
Why?
|
| Poly I-C | 1 | 2016 | 18 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2017 | 171 | 0.030 |
Why?
|
| Endosomes | 1 | 2016 | 79 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2008 | 426 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 37 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 111 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2017 | 211 | 0.030 |
Why?
|
| Ethambutol | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pyrazinamide | 1 | 2015 | 5 | 0.030 |
Why?
|
| Isoniazid | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 91 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 277 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Rifampin | 1 | 2015 | 23 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2011 | 899 | 0.030 |
Why?
|
| Colitis | 1 | 2018 | 244 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 205 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 97 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 161 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 385 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 334 | 0.030 |
Why?
|
| Algorithms | 2 | 2014 | 1875 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 236 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2014 | 126 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 136 | 0.030 |
Why?
|
| Cell Line | 2 | 2009 | 2495 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 2439 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 130 | 0.030 |
Why?
|
| Laboratories | 1 | 2013 | 44 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 22 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 127 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 1114 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1157 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 1097 | 0.030 |
Why?
|
| Skin Tests | 1 | 2013 | 44 | 0.030 |
Why?
|
| Multigene Family | 1 | 2014 | 203 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 104 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2003 | 2275 | 0.030 |
Why?
|
| Dust | 1 | 2013 | 26 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2015 | 509 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2013 | 80 | 0.030 |
Why?
|
| Oxidants | 1 | 2013 | 86 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 139 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 74 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 207 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 145 | 0.030 |
Why?
|
| Tanzania | 1 | 2012 | 47 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2018 | 944 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1057 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 284 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2012 | 22 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 225 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2012 | 68 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2011 | 13 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2013 | 298 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 78 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 371 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2012 | 88 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2011 | 14 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 948 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 48 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 226 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2013 | 92 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2011 | 49 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2011 | 67 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 55 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2011 | 65 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 44 | 0.020 |
Why?
|
| HapMap Project | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 219 | 0.020 |
Why?
|
| Genes, myc | 1 | 2011 | 39 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 131 | 0.020 |
Why?
|
| Feces | 1 | 2013 | 327 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 318 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Ataxin-7 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2011 | 36 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 599 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 15 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 275 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 188 | 0.020 |
Why?
|
| Heredity | 1 | 2010 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 164 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 414 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 274 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 1764 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2011 | 153 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2010 | 51 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 25 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 458 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 620 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 116 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 162 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 114 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 911 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 188 | 0.020 |
Why?
|
| Parthenogenesis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 51 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 135 | 0.020 |
Why?
|
| Cleavage Stage, Ovum | 1 | 2008 | 6 | 0.020 |
Why?
|
| Blastocyst | 1 | 2008 | 35 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 172 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 60 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 136 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 71 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 208 | 0.020 |
Why?
|
| Apoptosis | 2 | 2008 | 1717 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 74 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 138 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 3211 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 272 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 1117 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 70 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 232 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 85 | 0.020 |
Why?
|
| Hemoglobinometry | 1 | 2007 | 8 | 0.020 |
Why?
|
| Oxyhemoglobins | 1 | 2007 | 30 | 0.020 |
Why?
|
| Founder Effect | 1 | 2008 | 104 | 0.020 |
Why?
|
| Lupus Nephritis | 1 | 2009 | 77 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2008 | 85 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2008 | 140 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 447 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2007 | 7 | 0.020 |
Why?
|
| Omentum | 1 | 2008 | 73 | 0.020 |
Why?
|
| DNA Damage | 1 | 2009 | 371 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2007 | 21 | 0.020 |
Why?
|
| Students | 1 | 2009 | 169 | 0.020 |
Why?
|
| Transgenes | 1 | 2008 | 185 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2007 | 85 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 322 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 14 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
| Hypoxia, Brain | 1 | 2007 | 43 | 0.020 |
Why?
|
| Melphalan | 1 | 2007 | 98 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 84 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 511 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 809 | 0.020 |
Why?
|
| Polysomnography | 1 | 2007 | 151 | 0.020 |
Why?
|
| Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 61 | 0.020 |
Why?
|
| Vidarabine | 1 | 2007 | 143 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 306 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 328 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 192 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2011 | 509 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 114 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2007 | 156 | 0.020 |
Why?
|
| Sulfasalazine | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 357 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 661 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 67 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2007 | 134 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 135 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 814 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 112 | 0.020 |
Why?
|
| Uncertainty | 1 | 2006 | 74 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2006 | 67 | 0.020 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2005 | 10 | 0.020 |
Why?
|
| Nickel | 1 | 2005 | 13 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 543 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 645 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 117 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 261 | 0.020 |
Why?
|
| Gestational Age | 1 | 2006 | 323 | 0.020 |
Why?
|
| Blindness | 1 | 2005 | 39 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2007 | 277 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 397 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 374 | 0.020 |
Why?
|
| Copper | 1 | 2005 | 77 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 308 | 0.020 |
Why?
|
| Anxiety | 1 | 2007 | 308 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 353 | 0.020 |
Why?
|
| Patient Admission | 1 | 2005 | 114 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2004 | 58 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 2004 | 30 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2007 | 1130 | 0.020 |
Why?
|
| Cerebral Palsy | 1 | 2005 | 96 | 0.020 |
Why?
|
| Educational Status | 1 | 2005 | 194 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 370 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2004 | 31 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 92 | 0.010 |
Why?
|
| Cisplatin | 1 | 2006 | 617 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 2005 | 189 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2007 | 321 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2004 | 197 | 0.010 |
Why?
|
| Nimodipine | 1 | 2003 | 11 | 0.010 |
Why?
|
| Neutropenia | 1 | 2004 | 216 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2007 | 476 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 57 | 0.010 |
Why?
|
| Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 421 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 179 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2003 | 59 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 71 | 0.010 |
Why?
|
| Communicable Disease Control | 1 | 2003 | 50 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 187 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.010 |
Why?
|
| Sample Size | 1 | 2003 | 128 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2003 | 71 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 328 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 524 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Intracranial Hemorrhages | 1 | 2003 | 129 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 226 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 3147 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 783 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 561 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 434 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 343 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 967 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 472 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 682 | 0.010 |
Why?
|
| Carboplatin | 1 | 2002 | 304 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 2001 | 6 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 783 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 2001 | 26 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 698 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 696 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 519 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 352 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 458 | 0.010 |
Why?
|
| HIV-1 | 1 | 2001 | 166 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2362 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2003 | 500 | 0.010 |
Why?
|
| Hospitalization | 1 | 2004 | 876 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 741 | 0.010 |
Why?
|